Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic response (SVR), adherence, discontinuation, and HCV reinfection among PWID. A search of Medline, Embase, and Cochrane databases (between 2002 and January 2012) was conducted for primary articles/conference abstracts examining HCV treatment outcomes in PWID. Meta-analysis was used to obtain pooled estimates of SVR, adherence, discontinuation, and HCV reinfection.
- hepatitis C virus
- drug users
- sustained virologic response
- virus infection
Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S., Dore, G. J., Goldberg, D., & Hellard, M. E. (2013). Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clinical Infectious Diseases, 53(Suppl 2), S80-89. https://doi.org/10.1093/cid/cit306